Brensocatib

Unassigned

New Medicines

Non-cystic fibrosis-related bronchiectasis (NCFBE)

Information

New molecular entity
Insmed
Insmed

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

First in class reversible dipeptidyl peptidase 1 (DPP1) inhibitor. Blocks activation of neutrophils which accumulate in airways causing lung inflammation in chronic inflammatory lung diseases.[1]
Around 200,000 people are thought to be affected with NCFBE in England.[2]
Non-cystic fibrosis-related bronchiectasis (NCFBE)
Oral